PHARMACEUTICAL FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR

PROBLEM TO BE SOLVED: To provide a pharmaceutical formulation comprising HMG-CoA reductase inhibitor that is stable for the long term.SOLUTION: A pharmaceutical formulation comprises (A) HMG-CoA reductase inhibitor, (B) sugar alcohol, and (C) cellulose derivative (excluding crystalline cellulose) an...

Full description

Saved in:
Bibliographic Details
Main Author MOROFUJI RYO
Format Patent
LanguageEnglish
Japanese
Published 09.05.2016
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a pharmaceutical formulation comprising HMG-CoA reductase inhibitor that is stable for the long term.SOLUTION: A pharmaceutical formulation comprises (A) HMG-CoA reductase inhibitor, (B) sugar alcohol, and (C) cellulose derivative (excluding crystalline cellulose) and substantially comprises no crystalline cellulose.SELECTED DRAWING: None 【課題】長期にわたり安定なＨＭＧ−ＣｏＡレダクターゼ阻害薬を含む医薬製剤を提供する。【解決手段】（Ａ）ＨＭＧ−ＣｏＡレダクターゼ阻害薬、（Ｂ）糖アルコール、及び（Ｃ）セルロース誘導体（結晶セルロースを除く）を含み、実質的に結晶セルロースを含まないことを特徴とする、医薬製剤。【選択図】 なし
Bibliography:Application Number: JP20150190529